Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.70+0.80 (+5.03%)
Close on Nov 17, 2026Market cap $1.65BP/E –Yield –
Ultragenyx Pharmaceutical operating margin
Operating margin is operating income as a percentage of revenue.
Ultragenyx Pharmaceutical's operating margin for the twelve months ending Jun 30, 2026 was -73.6%. For fiscal 2025 it was -79.5%, against -95.7% the year before. The highest annual figure on record is -79.5% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -79.5% | +16.2 |
| FY2024 | Dec 31, 2024 | -95.7% | +35.4 |
| FY2023 | Dec 31, 2023 | -131.1% | +47.5 |
| FY2022 | Dec 31, 2022 | -178.6% | −70.0 |
| FY2021 | Dec 31, 2021 | -108.6% | +13.2 |
| FY2020 | Dec 31, 2020 | -121.8% | +287.2 |
| FY2019 | Dec 31, 2019 | -409.0% | +312.2 |
| FY2018 | Dec 31, 2018 | -721.2% | +11872.3 |
| FY2017 | Dec 31, 2017 | -12593.5% | +173877.9 |
| FY2016 | Dec 31, 2016 | -186471.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -35.0% | +29.6 |
| Q1 FY2026 | Mar 31, 2026 | -124.3% | −21.4 |
| Q4 FY2025 | Dec 31, 2025 | -54.7% | +19.6 |
| Q3 FY2025 | Sep 30, 2025 | -106.9% | −12.2 |
| Q2 FY2025 | Jun 30, 2025 | -64.7% | +14.5 |
| Q1 FY2025 | Mar 31, 2025 | -102.9% | +49.0 |
| Q4 FY2024 | Dec 31, 2024 | -74.3% | +21.5 |
| Q3 FY2024 | Sep 30, 2024 | -94.6% | +53.4 |
| Q2 FY2024 | Jun 30, 2024 | -79.1% | +57.5 |
| Q1 FY2024 | Mar 31, 2024 | -151.9% | +1.4 |
| Q4 FY2023 | Dec 31, 2023 | -95.8% | +45.1 |
| Q3 FY2023 | Sep 30, 2023 | -148.0% | +100.2 |
| Q2 FY2023 | Jun 30, 2023 | -136.6% | +21.9 |
| Q1 FY2023 | Mar 31, 2023 | -153.3% | +17.6 |
| Q4 FY2022 | Dec 31, 2022 | -140.9% | −17.9 |
| Q3 FY2022 | Sep 30, 2022 | -248.1% | −138.1 |
| Q2 FY2022 | Jun 30, 2022 | -158.5% | −63.3 |
| Q1 FY2022 | Mar 31, 2022 | -170.9% | −63.7 |
| Q4 FY2021 | Dec 31, 2021 | -123.0% | −18.0 |
| Q3 FY2021 | Sep 30, 2021 | -110.0% | −48.3 |
| Q2 FY2021 | Jun 30, 2021 | -95.2% | +7.0 |
| Q1 FY2021 | Mar 31, 2021 | -107.2% | +225.1 |
| Q4 FY2020 | Dec 31, 2020 | -105.0% | +160.4 |
| Q3 FY2020 | Sep 30, 2020 | -61.8% | +395.7 |
| Q2 FY2020 | Jun 30, 2020 | -102.2% | +363.6 |
| Q1 FY2020 | Mar 31, 2020 | -332.3% | +213.6 |
| Q4 FY2019 | Dec 31, 2019 | -265.4% | +290.2 |
| Q3 FY2019 | Sep 30, 2019 | -457.5% | +304.6 |
| Q2 FY2019 | Jun 30, 2019 | -465.8% | +276.0 |
| Q1 FY2019 | Mar 31, 2019 | -546.0% | +357.7 |
| Q4 FY2018 | Dec 31, 2018 | -555.6% | +3455.8 |
| Q3 FY2018 | Sep 30, 2018 | -762.1% | +41517.2 |
| Q2 FY2018 | Jun 30, 2018 | -741.8% | +1410238.2 |
| Q1 FY2018 | Mar 31, 2018 | -903.7% | +58360.3 |
| Q4 FY2017 | Dec 31, 2017 | -4011.4% | – |
| Q3 FY2017 | Sep 30, 2017 | -42279.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -1410980.0% | – |
| Q3 FY2016 | Sep 30, 2016 | -59264.0% | – |
See a number that looks wrong?